Navigation Links
Annual Drug Discovery Conferences Being Held in Boston MA, Spring 2012
Date:3/14/2012

FARMINGTON, Conn., March 14, 2012 /PRNewswire-iReach/ -- Global Information Inc. is excited to announce 4 significant Drug Discovery and Healthcare conferences scheduled for Boston, MA in the Spring of 2012.

8th Annual PEGS, Protein Engineering Summit
April 30 – May 4, 2012: Cambridge Healthtech Institute is hosting the Eighth Annual PEGS: Protein Engineering Summit in Boston, MA. This comprehensive event encompasses 12 tracks, 15 short courses, and a preconference partnering forum for showcasing early stage companies. Topics span from early stage discovery of new methods for protein expression and antibody engineering, to improved analytical techniques, and clinical results in the most promising areas of biotechnology. There is tremendous momentum and investment in biologics, and PEGS offers an unparalleled view of the field.

Additional information and Early Bird discounted rates are available at http://www.giiconference.com/chi214651-2012/

Next-Gen Kinase Inhibitors
June 4 - 6, 2012: Pioneers from across the rapidly maturing kinase inhibitors field will gather to explore the exciting question of what lies ahead at the Next-Gen Kinase Inhibitors Conference in Cambridge, MA. What is in store for the pharmaceutical industry and what new avenues are opening up for new technologies and methods as novel targets and therapeutic approaches are explored? What ground-breaking kinase indications are being discovered, and what other therapeutic areas are blossoming?

Topics to be explored include key issues around addressing resistance; selectivity versus safety; developing lead compounds; the integration of chemistry and biology; using promising techniques such as frag
'/>"/>

SOURCE Global Information, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology news :

1. Media alert: Press registration open for 2012 SIR Annual Scientific Meeting
2. Air Force Office of Scientific Research hosts annual program Spring Review
3. Research!America Annual Advocacy Awards Dinner
4. Highlights of the Biophysical Society 56th Annual Meeting
5. Chinese scientists Zhen-Yi Wang and Zhu Chen awarded 7th annual Szent-Gyorgyi Prize
6. 2012 SSR Annual Meeting: Call for abstracts
7. Toxicologists annual meeting in San Francisco to showcase the latest scientific achievements
8. Fate Therapeutics Announces Promising Data From Phase 1b Study of ProHema at the 2011 American Society of Hematology Annual Conference
9. UH Seidman Cancer Center researchers present at American Society of Hematology Annual Meeting
10. NYU Langone experts present at American College of Rheumatology 2011 Annual Meeting
11. NJIT grad students display work at 7th annual Research Day on Nov. 9
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased ... State of Washington,s Department of Licensing, ... and central issuance system for driver,s licenses and identification cards ... planning and development will start in January 2015, with enrollment ...
(Date:1/22/2015)... , Jan. 16, 2015  A man-made form of ... and other mental capabilities in adults with mild cognitive ... study led by researchers at Wake Forest Baptist Medical ... diagnosed with amnesic mild cognitive impairment (MCI) or mild ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) has ... Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, ... report to their offering. , ... be worn on the user,s body and have ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... Ore. In ecosystems around the world, the decline of ... is changing the face of landscapes from the tropics to ... published today in the journal Science shows for ... by humans and loss of prey combine to create global ...
... A team of scientists at LSU Health Sciences Center ... of E6-associated protein (E6AP), an enzyme that acts as a ... time, that the active form of E6AP is composed of ... the ability of nerve cells to "rewire" themselves in response ...
... new technology to squeeze more energy from the fuel release ... power plants do, according to a new analysis accepted for ... of the American Geophysical Union. The so-called "combined cycle" natural ... sulfur dioxide, which can worsen air quality. "Since more ...
Cached Biology News:Loss of large carnivores poses global conservation problem 2Loss of large carnivores poses global conservation problem 3LSUHSC research reveals structure of master regulator and new drug target for autism, cervical cancer 2New study: US power plant emissions down 2
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015   ... company, and Sequenom, Inc. (NASDAQ: SQNM ... a development agreement for next generation noninvasive prenatal ... Cypher,s genome interpretation technology, called Mantis™, to advance ...
(Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval application ... the use of Medtronic,s SynchroMed ® II implantable ... use with United Therapeutics, Remodulin ® (treprostinil) Injection ...
(Date:12/24/2014)... Louis, Missouri (PRWEB) December 23, 2014 GMO ... biotechnology company, Syngenta, are in the process of being consolidated ... case is In Re: Syngenta AG MIR 162 Corn Litigation, ... District of Kansas. , Management of the Syngenta GMO corn ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 The ... as its definition, classification, application and industry overview. ... and product cost structure. Production is separated by ... upstream raw materials, equipment, downstream client survey, marketing ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... 7 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc.,(TSX:SDI) today ... the fiscal year ended December 31, 2007., ... its EAA(TM) Endotoxin,Activity Assay, the only FDA ... is a systemic response to bacterial toxins ...
... CLARA, Calif., March 7 Finesse Solutions, LLC, ... sciences process,applications, and Nova Biomedical, Waltham, MA, a ... TruBio(TM) OS plug-in,for OPC connectivity between TruBio(TM) OS ... Basic 2 analyzers. Both companies confirmed that a,TruBio(TM) ...
... SAN DIEGO, March 6 Cadence Pharmaceuticals,Inc. (Nasdaq: ... in-licensing,developing and commercializing proprietary product candidates principally,for use ... will release its,fourth quarter and full year ended ... market on Wednesday, March 12, 2008., Cadence ...
Cached Biology Technology:Spectral announces 2007 financial results 2Spectral announces 2007 financial results 3Spectral announces 2007 financial results 4Spectral announces 2007 financial results 5Spectral announces 2007 financial results 6Spectral announces 2007 financial results 7Spectral announces 2007 financial results 8Spectral announces 2007 financial results 9Finesse Solutions, LLC Announces OPC Connectivity With Nova BioProfile 400 2Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008 2
See product name for description....
Request Info...
G-Protein Coupled Receptor Assay, For 500 assays. SPA. Category: Drug Screening & Cellular Assays, Assays ....
Panomer 9 oligodeoxynucleotides are random primers that are labeled at the 5' end with our proprietary QSY 7 dye and they are useful for assessing microarray spot morphology, hybridization potential ...
Biology Products: